Jeffrey Wilhite
Optometrist · Marrero, LANPI 1639424997
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,700 of the $85,811 with a category attached, or 70.7%. 22 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 55.9% of the total. 2025 is the largest year on record at $47,411, more than ten times the $515 reported in 2019. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $288.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$48K
- Harrow Eye, LLC$31K
- Optos, Inc.$2K
- Oyster Point Pharma, Inc.$844
- AbbVie$781
- Alcon$709
- plus $3K from 16 others
What the payments were for
- Speaking & faculty fees$60,70071%
- Travel & lodging$9,41411%
- Food & beverage$14,97417%
- Gifts$190%
- Entertainment$7031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 103 | $47,946 |
| Harrow Eye, LLC | 31 | $30,513 |
| Optos, Inc. | 12 | $2,259 |
| Oyster Point Pharma, Inc. | 25 | $844 |
| AbbVie(2 entities) | 17 | $781 |
| Alcon | 26 | $709 |
| Sun Pharmaceutical Industries Inc. | 14 | $396 |
| Johnson & Johnson Vision Care, Inc. | 12 | $372 |
| Dompe US, Inc. | 8 | $330 |
| Carl Zeiss Meditec USA, Inc. | 2 | $279 |
| Tarsus Pharmaceuticals, Inc. | 12 | $277 |
| Novartis | 10 | $204 |
| Coopervision Inc. | 7 | $199 |
| Kala Pharmaceuticals, Inc. | 3 | $171 |
| Eyevance Pharmaceuticals LLC | 7 | $164 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $118 |
| Glaukos Corporation | 2 | $37 |
| Ocular Therapeutix, Inc. | 1 | $29 |
| Carl Zeiss Meditec, Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sight Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$45,508
- XIIDRA$43,561
- VEVYE$30,176
- PANORAMIC OPHTHALMOSCOPE$2,077
- OCT OPHTHALMOSCOPE$1,386
- P200DTx$804
- NFC-700$788
- BLINK NUTRITEARS$400
- P200T$304
- P200TE$304
- P200TxE$304
- Precision 1$239
- CIRRUS HD-OCT$147
- VYZULTA$135
- RESTASIS MULTIDOSE$134
- TYRVAYA$133
- LUMIGAN$133
- CLARUS$132
- Acuvue$129
- VUITY$125
How this compares
$85,811 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 95 | $114,919 |
| RestasisCyclosporine | 45 | $58,311 |
| MieboPerfluorohexyloctane/Pf | 47 | $37,270 |
| EysuvisLoteprednol Etabonate | 25 | $16,015 |
| Fluorometholone | 43 | $3,336 |
| Latanoprost | 101 | $1,310 |
| Prednisolone Acetate | 34 | $1,199 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 22 | $378 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $47,946 | $152,189142 claims |
| AbbVieRestasis | $781 | $58,31145 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $171 | $16,01525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Marrero
- Robert KellyMarrero$26K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
- Robert JanotSulphur$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.